Rovi’s Value-Added US Risperidone Gets New Goal Date, Teva Ruled Out As Partner
Follows Teva’s Recent Launch Of Rovi’s Xeplion Generic In Spain
Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.
